• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel oral anticoagulants in gastroenterology practice.

作者信息

Desai Jay, Granger Christopher B, Weitz Jeffrey I, Aisenberg James

机构信息

Department of Medicine Division of Gastroenterology, New York University, New York, New York, USA.

出版信息

Gastrointest Endosc. 2013 Aug;78(2):227-39. doi: 10.1016/j.gie.2013.04.179. Epub 2013 May 29.

DOI:10.1016/j.gie.2013.04.179
PMID:23725876
Abstract
摘要

相似文献

1
Novel oral anticoagulants in gastroenterology practice.胃肠病学实践中的新型口服抗凝剂。
Gastrointest Endosc. 2013 Aug;78(2):227-39. doi: 10.1016/j.gie.2013.04.179. Epub 2013 May 29.
2
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
3
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.新型口服抗凝药物在预防心房颤动卒中方面的疗效和安全性的间接比较。
J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.
4
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.直接凝血酶和Xa因子抑制用于心房颤动患者的卒中预防
Hosp Pract (1995). 2013 Feb;41(1):26-36. doi: 10.3810/hp.2013.02.1010.
5
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.达比加群、利伐沙班和阿哌沙班治疗心房颤动的间接比较。
Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28.
6
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).非瓣膜性心房颤动患者停用利伐沙班与华法林的结局：ROCKET AF 试验（利伐沙班每日 1 次口服、直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞的随机临床试验）分析。
J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.
7
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.使用网状Meta分析比较达比加群、利伐沙班和阿哌沙班在房颤患者中的疗效和安全性。
Int Angiol. 2012 Aug;31(4):330-9.
8
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.用于心房颤动患者预防卒中的新型口服抗凝药。
Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006.
9
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.长期接受直接口服抗凝剂、凝血酶或因子 Xa 抑制剂治疗的患者的大出血并发症和紧急手术的处理：围手术期止血工作组（GIHP）的建议-2013 年 3 月。
Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.
10
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.利伐沙班每日一次、口服、直接 Xa 因子抑制与维生素 K 拮抗剂用于预防卒中和心房颤动的栓塞试验：ROCKET AF 研究的原理和设计。
Am Heart J. 2010 Mar;159(3):340-347.e1. doi: 10.1016/j.ahj.2009.11.025.

引用本文的文献

1
Safety and effectiveness of Rivaroxaban, Dabigatran and Apixaban in patients with non-valvular atrial fibrillation for stroke prophylaxis.利伐沙班、达比加群和阿哌沙班用于非瓣膜性心房颤动患者预防卒中的安全性和有效性。
BMC Neurol. 2025 Jul 17;25(1):294. doi: 10.1186/s12883-025-04306-1.
2
The effect of anticoagulation therapy on the surgical outcomes of minimally invasive major gastrointestinal surgery.抗凝治疗对微创大型胃肠手术手术结局的影响。
Surg Endosc. 2025 Feb;39(2):1016-1024. doi: 10.1007/s00464-024-11465-8. Epub 2024 Dec 16.
3
Thromboembolic prevention in athletes: management of anticoagulation in sports players affected by atrial fibrillation.
运动员的血栓栓塞预防：房颤患者运动员的抗凝管理
Front Pharmacol. 2024 May 10;15:1384213. doi: 10.3389/fphar.2024.1384213. eCollection 2024.
4
Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis.不同 P-糖蛋白/细胞色素 CYP3A4 抑制剂口服抗凝药的有效性和安全性：网络荟萃分析。
Curr Pharm Des. 2024;30(15):1167-1177. doi: 10.2174/0113816128293940240315073345.
5
Effect of aspirin, warfarin, and proton-pump inhibitors on performance of fecal immunochemical test in colorectal cancer screening: a systematic review and meta-analysis.阿司匹林、华法林和质子泵抑制剂对结直肠癌筛查中粪便免疫化学试验性能的影响：系统评价和荟萃分析。
Clin Exp Med. 2023 Dec;23(8):4355-4368. doi: 10.1007/s10238-023-01196-w. Epub 2023 Oct 7.
6
Assessment of delayed bleeding after endoscopic submucosal dissection of early-stage gastrointestinal tumors in patients receiving direct oral anticoagulants.评估直接口服抗凝剂治疗患者内镜黏膜下剥离术治疗早期胃肠道肿瘤后的延迟出血。
World J Gastroenterol. 2023 May 21;29(19):2916-2931. doi: 10.3748/wjg.v29.i19.2916.
7
Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion.房颤患者胃肠道出血的管理和口服抗凝药物的恢复：多学科讨论。
Am J Cardiovasc Drugs. 2023 Jul;23(4):407-418. doi: 10.1007/s40256-023-00582-9. Epub 2023 May 5.
8
Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.直接口服抗凝剂（DOACs）的药物相互作用：从药理学到临床实践
Pharmaceutics. 2022 May 24;14(6):1120. doi: 10.3390/pharmaceutics14061120.
9
Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors.聚焦于Xa因子抑制剂管理的胃内镜黏膜下剥离术后出血
J Gastric Cancer. 2022 Mar;22(1):47-55. doi: 10.5230/jgc.2022.22.e2. Epub 2022 Feb 23.
10
Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database - A Case Study.通过对应分析意大利药物警戒数据库的数据研究直接口服抗凝剂（DOACs）和华法林与出血风险的关联——一项案例研究
Front Pharmacol. 2021 Dec 7;12:790740. doi: 10.3389/fphar.2021.790740. eCollection 2021.